These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

400 related items for PubMed ID: 17532577

  • 1. Correlation of molecular response as measured by 18-FDG positron emission tomography with outcome after chemoradiotherapy in patients with esophageal carcinoma.
    Konski AA, Cheng JD, Goldberg M, Li T, Maurer A, Yu JQ, Haluszka O, Scott W, Meropol NJ, Cohen SJ, Freedman G, Weiner LM.
    Int J Radiat Oncol Biol Phys; 2007 Oct 01; 69(2):358-63. PubMed ID: 17532577
    [Abstract] [Full Text] [Related]

  • 2. Postchemoradiotherapy positron emission tomography predicts pathologic response and survival in patients with esophageal cancer.
    Jayachandran P, Pai RK, Quon A, Graves E, Krakow TE, La T, Loo BW, Koong AC, Chang DT.
    Int J Radiat Oncol Biol Phys; 2012 Oct 01; 84(2):471-7. PubMed ID: 22381904
    [Abstract] [Full Text] [Related]

  • 3. Utility of PET, CT, and EUS to identify pathologic responders in esophageal cancer.
    Swisher SG, Maish M, Erasmus JJ, Correa AM, Ajani JA, Bresalier R, Komaki R, Macapinlac H, Munden RF, Putnam JB, Rice D, Smythe WR, Vaporciyan AA, Walsh GL, Wu TT, Roth JA.
    Ann Thorac Surg; 2004 Oct 01; 78(4):1152-60; discussion 1152-60. PubMed ID: 15464463
    [Abstract] [Full Text] [Related]

  • 4. Role of Repeat 18F-Fluorodeoxyglucose Positron Emission Tomography Examination in Predicting Pathologic Response Following Neoadjuvant Chemoradiotherapy for Esophageal Adenocarcinoma.
    Kukar M, Alnaji RM, Jabi F, Platz TA, Attwood K, Nava H, Ben-David K, Mattson D, Salerno K, Malhotra U, Kanehira K, Gannon J, Hochwald SN.
    JAMA Surg; 2015 Jun 01; 150(6):555-62. PubMed ID: 25902198
    [Abstract] [Full Text] [Related]

  • 5. 2-Fluoro-2-deoxy-D-glucose positron emission tomography imaging is predictive of pathologic response and survival after preoperative chemoradiation in patients with esophageal carcinoma.
    Swisher SG, Erasmus J, Maish M, Correa AM, Macapinlac H, Ajani JA, Cox JD, Komaki RR, Hong D, Lee HK, Putnam JB, Rice DC, Smythe WR, Thai L, Vaporciyan AA, Walsh GL, Wu TT, Roth JA.
    Cancer; 2004 Oct 15; 101(8):1776-85. PubMed ID: 15386332
    [Abstract] [Full Text] [Related]

  • 6. The role of qualitative and quantitative analysis of F18-FDG positron emission tomography in predicting pathologic response following chemoradiotherapy in patients with esophageal carcinoma.
    Klayton T, Li T, Yu JQ, Keller L, Cheng J, Cohen SJ, Meropol NJ, Scott W, Xu-Welliver M, Konski A.
    J Gastrointest Cancer; 2012 Dec 15; 43(4):612-8. PubMed ID: 22777832
    [Abstract] [Full Text] [Related]

  • 7. Value of baseline positron emission tomography for predicting overall survival in patient with nonmetastatic esophageal or gastroesophageal junction carcinoma.
    Hong D, Lunagomez S, Kim EE, Lee JH, Bresalier RS, Swisher SG, Wu TT, Morris J, Liao Z, Komaki R, Ajani JA.
    Cancer; 2005 Oct 15; 104(8):1620-6. PubMed ID: 16118804
    [Abstract] [Full Text] [Related]

  • 8. Fluorodeoxyglucose positron emission tomography for evaluating early response during neoadjuvant chemoradiotherapy in patients with potentially curable esophageal cancer.
    van Heijl M, Omloo JM, van Berge Henegouwen MI, Hoekstra OS, Boellaard R, Bossuyt PM, Busch OR, Tilanus HW, Hulshof MC, van der Gaast A, Nieuwenhuijzen GA, Bonenkamp HJ, Plukker JT, Cuesta MA, Ten Kate FJ, Pruim J, van Dekken H, Bergman JJ, Sloof GW, van Lanschot JJ.
    Ann Surg; 2011 Jan 15; 253(1):56-63. PubMed ID: 21233607
    [Abstract] [Full Text] [Related]

  • 9. Time course of tumor metabolic activity during chemoradiotherapy of esophageal squamous cell carcinoma and response to treatment.
    Wieder HA, Brücher BL, Zimmermann F, Becker K, Lordick F, Beer A, Schwaiger M, Fink U, Siewert JR, Stein HJ, Weber WA.
    J Clin Oncol; 2004 Mar 01; 22(5):900-8. PubMed ID: 14990646
    [Abstract] [Full Text] [Related]

  • 10. Outcomes of patients with esophageal cancer staged with [¹⁸F]fluorodeoxyglucose positron emission tomography (FDG-PET): can postchemoradiotherapy FDG-PET predict the utility of resection?
    Monjazeb AM, Riedlinger G, Aklilu M, Geisinger KR, Mishra G, Isom S, Clark P, Levine EA, Blackstock AW.
    J Clin Oncol; 2010 Nov 01; 28(31):4714-21. PubMed ID: 20876421
    [Abstract] [Full Text] [Related]

  • 11. FDG-PET/CT tumor segmentation-derived indices of metabolic activity to assess response to neoadjuvant therapy and progression-free survival in esophageal cancer: correlation with histopathology results.
    Mamede M, Abreu-E-Lima P, Oliva MR, Nosé V, Mamon H, Gerbaudo VH.
    Am J Clin Oncol; 2007 Aug 01; 30(4):377-88. PubMed ID: 17762438
    [Abstract] [Full Text] [Related]

  • 12. Predictive value of nodal maximum standardized uptake value of pretreatment [18F]fluorodeoxyglucose positron emission tomography imaging in patients with esophageal cancer.
    Yap WK, Chang YC, Tseng CK, Hsieh CH, Chao YK, Su PJ, Hou MM, Yang CK, Pai PC, Lin CR, Hsieh CE, Wu YY, Hung TM.
    Dis Esophagus; 2017 Aug 01; 30(8):1-10. PubMed ID: 28575243
    [Abstract] [Full Text] [Related]

  • 13. 18F-FDG PET in patients with esophageal squamous cell carcinoma undergoing curative surgery: prognostic implications.
    Choi JY, Jang HJ, Shim YM, Kim K, Lee KS, Lee KH, Choi Y, Choe YS, Kim BT.
    J Nucl Med; 2004 Nov 01; 45(11):1843-50. PubMed ID: 15534053
    [Abstract] [Full Text] [Related]

  • 14. Prognostic value of metabolic response measured by 18F-FDG-PET in oesophageal cancer patients treated with definitive chemoradiotherapy.
    Onal C, Torun N, Guler OC, Yildirim BA.
    Nucl Med Commun; 2016 Dec 01; 37(12):1282-1289. PubMed ID: 27612030
    [Abstract] [Full Text] [Related]

  • 15. Lack of fludeoxyglucose F 18 uptake in posttreatment positron emission tomography as a significant predictor of survival after subsequent surgery in multimodality treatment for patients with locally advanced esophageal squamous cell carcinoma.
    Higuchi I, Yasuda T, Yano M, Doki Y, Miyata H, Tatsumi M, Fukunaga H, Takiguchi S, Fujiwara Y, Hatazawa J, Monden M.
    J Thorac Cardiovasc Surg; 2008 Jul 01; 136(1):205-12, 212.e1-3. PubMed ID: 18603077
    [Abstract] [Full Text] [Related]

  • 16. The value of ¹⁸F-FDG PET/CT in assessment of metabolic response in esophageal cancer for prediction of histopathological response and survival after preoperative chemoradiotherapy.
    Myslivecek M, Neoral C, Vrba R, Vomackova K, Cincibuch J, Formanek R, Koranda P, Zapletalova J.
    Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2012 Jun 01; 156(2):171-9. PubMed ID: 22660205
    [Abstract] [Full Text] [Related]

  • 17. Assessment of treatment response and recurrence in esophageal carcinoma based on tumor length and standardized uptake value on positron emission tomography-computed tomography.
    Roedl JB, Harisinghani MG, Colen RR, Fischman AJ, Blake MA, Mathisen DJ, Mueller PR.
    Ann Thorac Surg; 2008 Oct 01; 86(4):1131-8. PubMed ID: 18805147
    [Abstract] [Full Text] [Related]

  • 18. Predictive value of 18-fluoro-deoxy-glucose-positron emission tomography (18F-FDG-PET) in the identification of responders to chemoradiation therapy for the treatment of locally advanced esophageal cancer.
    Levine EA, Farmer MR, Clark P, Mishra G, Ho C, Geisinger KR, Melin SA, Lovato J, Oaks T, Blackstock AW.
    Ann Surg; 2006 Apr 01; 243(4):472-8. PubMed ID: 16552197
    [Abstract] [Full Text] [Related]

  • 19. Metabolic tumor width parameters as determined on PET/CT predict disease-free survival and treatment response in squamous cell carcinoma of the esophagus.
    Roedl JB, Halpern EF, Colen RR, Sahani DV, Fischman AJ, Blake MA.
    Mol Imaging Biol; 2009 Apr 01; 11(1):54-60. PubMed ID: 18769974
    [Abstract] [Full Text] [Related]

  • 20. Prediction of response to definitive chemoradiotherapy in esophageal cancer using positron emission tomography.
    Kato H, Fukuchi M, Miyazaki T, Nakajima M, Tanaka N, Inose T, Kimura H, Faried A, Saito K, Sohda M, Fukai Y, Masuda N, Manda R, Ojima H, Tsukada K, Oriuchi N, Endo K, Nonaka T, Shioya M, Ishikawa H, Sakurai H, Nakano T, Kuwano H.
    Anticancer Res; 2007 Apr 01; 27(4C):2627-33. PubMed ID: 17695425
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.